landscape
Biomarker-Development
Coverage 5%
Whitespace 95% where missions and gaps live
Components measured 7 / 7 100% of formula weight
Formula breakdown
Each component is a normalized subscore in [0, 1]. The overall coverage is a weighted sum: components without a measurement (—) do not contribute. Bar lengths show the raw subscore; the contribution column shows weight × subscore (i.e. how many points this row added to the overall coverage).
Component Weight Subscore Contribution
evidence quality 20% 0%
paper density 15% 0%
hypothesis density 15% 0%
KG edge density 15% 0%
citation completeness 15% 0%
debate depth 10% 0%
trial coverage 10% 5%
Missions in this landscape
No missions are targeting this landscape yet.
Top open gaps (7)
- What biomarkers can distinguish Aβ-dependent versus Aβ-independent phases of tau pathology progression? unknown15d ago
- How can metabolomic biomarkers overcome participant heterogeneity to achieve diagnostic precision? unknown21d ago
- Why does p-tau181 show superior freeze-thaw stability compared to amyloid peptides in plasma? unknown22d ago
- What biomarkers can reliably distinguish beneficial from detrimental TREM2 activation states in patients? unknown22d ago
- What is the optimal sampling frequency for CSF lactate/pyruvate ratios to detect therapeutic response? unknown22d ago
- What biomarkers can reliably measure real-time glymphatic function to guide sleep-based neurodegeneration therapies? unknown22d ago
- What biomarkers can distinguish pathological vs protective TREM2+ microglial populations in vivo? unknown22d ago